Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a written consent form agreeing to take part in the study and allowing their personal health information to be shared.
• People who have been confirmed through a tissue or cell sample test to have adenocarcinoma of the pancreas (a specific type of pancreatic cancer) with no sign that the cancer has spread to distant parts of the body.
• People whose overall health means surgery to remove the pancreatic cancer has not been ruled out, as assessed by the surgical team involved in the trial.
• People who are willing to have a biopsy (a small tissue sample taken using a special imaging-guided procedure) of the pancreatic mass before and after treatment.
• People whose cancer is measurable or can otherwise be assessed using standard imaging criteria, and whose cancer is classified as resectable (able to be surgically removed), borderline resectable, or locally advanced but not yet spread further.
• People who are generally well enough to carry out daily activities with no restriction or only mild limitations (confirmed using a standard medical scoring system called ECOG 0 or 1).
• People who have not previously received chemotherapy, radiation therapy, or surgery for their pancreatic cancer.
• People who are 18 years of age or older.
• People whose liver, kidneys, and other organs are functioning adequately at the time of joining the study.
• People who have a life expectancy of at least 6 months.

Who may not be able to join:

• People who have signs that their pancreatic cancer has come back in the same area or has spread to other parts of the body.
• People who have had another cancer within the past 5 years, except for certain treated cancers that are generally considered low-risk (such as some cervical or vulvar pre-cancers, treated skin cancer, or certain early-stage bladder tumours — confirm with trial site).
• People who have a known allergy or serious sensitivity to any of the chemotherapy drugs used in this trial (5-fluorouracil, oxaliplatin, irinotecan, or related compounds).
• People who are known to have a deficiency of an enzyme called DPD (dihydropyrimidine dehydrogenase), which affects how the body breaks down certain chemotherapy drugs.
• People who have taken part in another experimental drug study within the 4 weeks before starting this trial, or who would be taking part in another experimental drug study at the same time (except for other clinical trials where the same standard chemotherapy combination is being used).
• People who have certain serious health conditions, including a heart attack in the past 6 months, significant heart failure (classified as NYHA Class III or IV), or an active infection currently requiring intravenous (IV) antibiotics.
• People who have a history of, or are suspected to have, a liver condition called Gilbert's syndrome, or who carry a specific genetic variation (UGT1A1*28) that affects how the body processes one of the chemotherapy drugs (confirm with trial site).
• People who already have moderate to severe nerve damage causing numbness, tingling, or pain (known as peripheral neuropathy, grade 2 or higher).
• People who have had major surgery, an open biopsy, or a serious physical injury within the 4 weeks before starting the trial.
• People who are not able or not willing to stop taking the antifungal medication ketoconazole or the herbal supplement St John's Wort during the trial.
• People who are pregnant or currently breastfeeding.
• People whose personal, family, social, or geographic circumstances may make it difficult to follow the study schedule and attend required appointments (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.